Videos

At the 2023 ASCO Gastrointestinal Symposium, Josep Tabernero, MD, shared results from the phase 3 trial evaluating trifluridine/tipiracil plus bevacizumab for patients with refractory colorectal cancer.

At the 2023 ASCO Gastrointestinal Symposium, Laura Dawson, MD, shares updated data from the NRG/RTOG 1112 trial evaluating stereotactic body radiotherapy plus sorafenib compared with sorafenib for hepatocellular carcinoma.

At the 2023 ASCO Gastrointestinal Symposium, Laura Dawson, MD, shares results from a study evaluating palliative radiotherapy for hepatocellular carcinoma and liver metastases.

At the 2023 ASCO Gastrointestinal Symposium, Kohei Shitara, MD, presents first results from a phase 3 study evaluating zolbetuximab plus modified FOLFOX6 in the first-line setting for patients with claudin-18.2-positive/HER2-negative locally...

At the 2022 San Antonio Breast Cancer Symposium, Joanne Kotsopoulos, PhD, discusses the risks certain hormonal exposures can pose for BRCA1/2 carriers.

Mark Litzow, MD, presents findings from a phase 3 trial showing the addition of blinatumomab to consolidation chemotherapy improves overall survival in patients with newly diagnosed B-lineage ALL.

Srdan Verstovsek, MD, discusses the long-term safety of momelotinib in patients with high- and intermediate-risk myelofibrosis, using data from 3 randomized controlled trials: SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM.

Nicholas Short, MD, presents findings from an analysis exploring simultaneous ponatinib and blinatumomab treatment for patients with newly diagnosed Philadelphia chromosome-positive ALL.

Lucia Masarova, MD discusses findings from a phase 2 study showing long-term durability of responses and disease control with pegylated interferon in patients with essential thrombocythemia and polycythemia vera after 15 years.